Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2012-11-15 Regulatory Filings
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2012
Regulatory Filings
2012-11-15 English
FORM 10-Q
Interim / Quarterly Report Q3 2012
2012-11-09 English
Regulatory Filings 2012
Regulatory Filings Classification · 95% confidence The document is a letter from Novavax, Inc. to the SEC Division of Corporate Finance responding to verbal comments on previously filed SEC reports, specifically the Form 10-K for the year ended December 31, 2011, and Form 10-Q for the quarter ended March 31, 2012. The letter discusses proposed disclosures to be included in future periodic reports, clarifications on revenue recognition policies, and responses to SEC staff comments. It does not contain actual financial statements or substantive financial data but rather addresses regulatory comments and proposed future disclosures. The document is a regulatory correspondence related to SEC filings, not the filings themselves. Therefore, it fits best under Regulatory Filings (RNS).
2012-10-30 English
PRELIMINARY PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a Preliminary Prospectus Supplement filed pursuant to Rule 424(b)(5) related to a shelf registration statement. It details an offering of common stock, including the number of shares, price, use of proceeds, dilution, legal matters, and plan of distribution. It references the Securities and Exchange Commission (SEC) and includes typical prospectus language about risk factors, incorporation by reference of prior filings (including 10-K and 10-Q), and disclaimers. The document is clearly an offering document related to capital raising activities, specifically a stock offering. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. It is not an Annual Report, Earnings Release, or any other report type, but a financing prospectus supplement.
2012-10-23 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 23, 2012. It announces a financing transaction where the company agreed to sell shares directly to certain investors. The document includes legal opinions and a press release about the offering. There are no financial statements or detailed financial data presented, only an announcement of a capital raising event. The content fits the description of a Capital/Financing Update rather than a full financial report or earnings release. The document length is 4221 characters, which is consistent with a brief announcement rather than a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2012-10-23 English
Regulatory Filings 2012
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC referencing prior filings of Form 10-K and Form 10-Q for specific periods. It confirms receipt of SEC's oral comments and states a future response will be provided. The document itself does not contain financial data or the actual reports but is a correspondence related to regulatory review. The length is short (998 characters), and it is primarily a communication or confirmation letter rather than a report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory correspondence.
2012-10-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.